Natco Pharma FY26 profit falls 25%; Q4 EBITDA margin at 25.1%
Published on: June 4, 2026, 2:59 p.m. | Source: scanx.trade
Natco Pharma reported a 25% decline in consolidated net profit to ₹14,185 million for FY26, with total revenue decreasing to ₹43,759 million. Q4 net profit fell to ₹2,690 million, and EBITDA margin contracted to 25.1% from 47.7% year-on-year, including a one-time deferred tax benefit of ₹1,150 million. The agro chemicals segment reported a loss of ₹198 crore, and the board approved a demerger scheme for this business into NATCO Crop Health Sciences Limited.
